journal article·2023-10Open access

The effect of electrostatic high pressure nebulization on the stability, activity and ex vivo distribution of ionic self-assembled nanomedicines

Helena Braet, Valentina Andretto, Remco Mariën, Beyza Yücesan, Stefan van der Vegte, Ragna Haegebaert, Giovanna Lollo, Stefaan C. De Smedt, Katrien Remaut

Acta Biomaterialia· Volume 170

Abstract

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is applied to treat unresectable peritoneal metastasis (PM), an advanced, end-stage disease with a poor prognosis. Electrostatic precipitation of the aerosol (ePIPAC) is aimed at improving the intraperitoneal (IP) drug distribution and tumor penetration. Also, the combination of nanoparticles (NPs) as drug delivery vehicles and IP aerosolization as administration method has been proposed as a promising tool to treat PM. There is currently limited knowledge on how electrostatic precipitation (ePIPAC) and high pressure nebulization (PIPAC) affects the performance of electrostatically formed complexes. Therefore, the stability, in vitro activity and ex vivo distribution and tissue penetration of negatively charged cisPt-pArg-HA NPs and positively charged siRNA-RNAiMAX NPs was evaluated following PIPAC and ePIPAC. Additionally, a multidirectional Medspray® nozzle was developed and compared with the currently used Capnopen® nozzle. For both NP types, PIPAC and ePIPAC did not negatively influence the in vitro activity, although limited aggregation of siRNA-RNAiMAX NPs was observed following nebulization with the Capnopen®. Importantly, ePIPAC was linked to a more uniform distribution and higher tissue penetration of the NPs aerosolized by both nozzles, independent on the NPs charge. Finally, compared to the Capnopen®, an increased NP deposition was observed at the top of the ex vivo model following aerosolization with the Medspray® nozzle, which indicates that this device possesses great potential for IP drug delivery purposes. STATEMENT OF SIGNIFICANCE: Aerosolized drug delivery in the peritoneal cavity holds great promise to treat peritoneal cancer. In addition, electrostatic precipitation of the aerosol to the peritoneal tissue is aimed at improving the drug distribution and tumor penetration. The combination of nanoparticles (NPs), which are nano-sized drug delivery vehicles, and aerosolization has been proposed as a promising tool to treat peritoneal cancer. However, there is currently limited knowledge on how electrostatic precipitation and aerosolization affect the performance of electrostatically formed NPs. Therefore, the stability, activity, distribution and penetration of negatively and positively charged NPs was evaluated after aerosolization and electrostatic precipitation. Additionally, to further optimize the local drug distribution, a multidirectional spray nozzle was developed and compared with the currently used nozzle.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Intraperitoneal and Appendiceal Malignancies · Inhalation and Respiratory Drug Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. The histophysiology and pathophysiology of the peritoneum10.1016/j.tice.2016.11.004 ↗
2. Intraperitoneal therapy for peritoneal cancer10.2217/fon.10.100 ↗
3. Looking up: recent advances in understanding and treating peritoneal carcinomatosis
4. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis10.1016/j.ejso.2015.08.172 ↗
5. Malignant peritoneal mesothelioma
6. Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective10.1016/j.suronc.2014.03.004 ↗
7. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion10.1080/17425247.2020.1736551 ↗
8. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer
9. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy10.1245/s10434-013-3213-1 ↗
10. The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review10.21037/jgo-20-497 ↗
11. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC)10.3390/cancers12010034 ↗
12. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma10.1515/pp-2019-0010 ↗
13. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study10.1177/1758835919846402 ↗
14. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study10.1016/j.ejso.2018.02.014 ↗
15. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): results of a single-center experience and register study10.5230/jgc.2018.18.e37 ↗
16. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications10.1016/S1470-2045(19)30318-3 ↗
17. Intraperitoneal aerosolized drug delivery: technology, recent developments, and future outlook10.1016/j.addr.2020.10.015 ↗
18. Scintigraphic peritoneography reveals a non-uniform 99m Tc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model10.1007/s00464-017-5652-4 ↗
19. Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application10.1515/pp-2016-0005 ↗
20. Electrostatic intraperitoneal aerosol delivery of nanoparticles: proof of concept and preclinical validation10.1002/adhm.202000655 ↗
21. Enhanced intraperitoneal delivery of charged, aerosolized curcumin nanoparticles by electrostatic precipitation10.2217/nnm-2020-0373 ↗
22. Synergy between Intraperitoneal Aerosolization (PIPAC) and cancer nanomedicine: cisplatin-loaded polyarginine-hyaluronic acid nanocarriers efficiently eradicate peritoneal metastasis of advanced human ovarian cancer
23. High-pressure nebulization as application route for the peritoneal administration of siRNA complexes10.1002/mabi.201700024 ↗
24. L. Van De Sande, M. Graversen, M. Hubner, M. Pocard, M. Reymond, M. Vaira, S. Cosyns, W. Willaert, W. Ceelen, Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis – a phase I first-in-human study,Pleura Peritoneum 3 (2018) 20180112. doi:10.1515/pp-2018-0112.10.1515/pp-2018-0112 ↗
25. Ceelen · 2015
26. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?10.1016/j.addr.2016.07.001 ↗
27. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis10.1002/wnan.1670 ↗
28. A negatively charged Pt( iv ) prodrug for electrostatic complexation with polymers to overcome cisplatin resistance10.1039/C9TB00155G ↗
29. Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis10.3390/cancers11070906 ↗
30. High Pressure Nebulization (PIPAC) versus injection for the intraperitoneal administration of mRNA complexes10.1007/s11095-019-2646-z ↗
31. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC)10.1007/s00464-016-5174-5 ↗
32. Evaluation of a novel prototype for pressurized intraperitoneal aerosol chemotherapy10.3390/cancers12030633 ↗
33. Intrathoracic aerosol chemotherapy via spray-catheter
34. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) via endoscopical microcatheter system10.21873/anticanres.12613 ↗
35. Creating nanocrystallized chemotherapy: the differences in pressurized aerosol chemotherapy (PAC) via intracavitary (IAG) and extracavitary aerosol generation (EAG) regarding particle generation, morphology and structure10.7150/jca.39097 ↗
36. Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): technical description, experimental validation and first proof of concept10.3762/bjnano.8.272 ↗
37. A prototype single-port device for pressurized intraperitoneal aerosol chemotherapy. Technical feasibility and local drug distribution10.1590/s0102-865020170120000007 ↗
38. Peritoneal nebulizer: a novel technique for delivering intraperitoneal therapeutics in laparoscopic surgery to prevent locoregional recurrence
39. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial
40. Aerosolized intraperitoneal local anesthetic for laparoscopic surgery: a randomized, double-blinded, placebo-controlled trial10.1007/s00268-015-2973-0 ↗
41. Total systemic ropivacaine concentrations following aerosolized intraperitoneal delivery using the AeroSurge10.1016/j.jclinane.2013.07.013 ↗
42. Intraperitoneal nebulization versus intraperitoneal instillation of ropivacaine for postoperative pain management following laparoscopic donor nephrectomy10.4097/kja.d.18.00290 ↗
43. Postoperative ANALGESIA after laparoscopic ovarian cyst resection: double-blind multicenter randomized control trial comparing intraperitoneal nebulization and peritoneal instillation of ropivacaine10.1016/j.jmig.2015.01.032 ↗
44. Statistical comparison between the physical properties of the particles on standard BhioStilo PIPAC and ultrasonic PIPAC10.1016/j.ejso.2021.12.319 ↗
45. Evaluation of the feasibility of ultrasonic aerosolization of therapeutic substance in animal model10.1016/j.ejso.2021.12.318 ↗
46. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug10.1158/1078-0432.CCR-13-1536 ↗
47. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo10.1038/sj.gt.3302425 ↗
48. Hybrid core-shell particles for mRNA systemic delivery10.1016/j.jconrel.2022.11.042 ↗
49. Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery10.1016/j.ejpb.2020.02.008 ↗
50. Fiji: an open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
51. Degradation of lipid based drug delivery formulations during nebulization10.1016/j.chemphys.2021.111192 ↗
52. Lipoplex morphologies and their influences on transfection efficiency in gene delivery10.1016/j.jconrel.2007.08.022 ↗
53. Disregarded effect of biological fluids in siRNA delivery: human ascites fluid severely restricts cellular uptake of nanoparticles10.1021/acsami.5b08805 ↗
54. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis10.1042/bj20031253 ↗
55. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles10.2147/IJN.S36111 ↗
56. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) through a single port: alternative delivery for the control of peritoneal metastases10.1590/0100-6991e-20181909 ↗
57. Assessment of the aerosol distribution pattern of a single-port device for intraperitoneal administration of therapeutic substances10.1007/s00464-019-07043-y ↗
58. Aerosol distribution pattern of a single-port device: new perspective treatment for peritoneal carcinomatosis in Brazil